Dalzanemdor

Dalzanemdor ( ; development code SAGE-718) is experimental drug that was previously investigated for the treatment of neurological disorders and cognitive impairment.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Dalzanemdor ( ; development code SAGE-718) is experimental drug that was previously investigated for the treatment of neurological disorders and cognitive impairment. It acts as a positive allosteric modulator of the NMDA receptor, whose activity is essential for learning, memory, and cognition. Dalzanemdor is an analogue of the neurosteroid 24S-hydroxycholesterol.

As of 2022, dalzanemdor is in Phase II clinical trials for Alzheimer's disease, Parkinson's disease, and Huntington's disease. As of 2024, Sage Therapeutics had discontinued development of dalzanemdor following negative clinical trial results.

Dalzanemdor (SAGE-718) - Sage Therapeutics

Text derived from https://en.wikipedia.org/w/index.php?oldid=1357844496 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

9 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.